JP2003508059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003508059A5 JP2003508059A5 JP2001520901A JP2001520901A JP2003508059A5 JP 2003508059 A5 JP2003508059 A5 JP 2003508059A5 JP 2001520901 A JP2001520901 A JP 2001520901A JP 2001520901 A JP2001520901 A JP 2001520901A JP 2003508059 A5 JP2003508059 A5 JP 2003508059A5
- Authority
- JP
- Japan
- Prior art keywords
- serum
- homocysteine
- concentration
- vitamin
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002966 Serum Anatomy 0.000 description 26
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 20
- 108010047320 Pepsinogen A Proteins 0.000 description 15
- 229930003779 Vitamin B12 Natural products 0.000 description 13
- 125000003346 cobalamin group Chemical group 0.000 description 13
- 235000019163 vitamin B12 Nutrition 0.000 description 13
- 239000011715 vitamin B12 Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002381 Plasma Anatomy 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004907 Glands Anatomy 0.000 description 4
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 4
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 4
- 102000024070 binding proteins Human genes 0.000 description 4
- 108091007650 binding proteins Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 201000011528 vascular disease Diseases 0.000 description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 206010017860 Gastritis atrophic Diseases 0.000 description 2
- 206010061256 Ischaemic stroke Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 108010066264 gastrin 17 Proteins 0.000 description 2
- 201000010238 heart disease Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000001502 supplementation Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 210000001156 Gastric Mucosa Anatomy 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 208000008459 Hyperhomocysteinemia Diseases 0.000 description 1
- 229940039696 Lactobacillus Drugs 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GKDWRERMBNGKCZ-RNXBIMIWSA-N Little gastrin I Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 208000002670 Vitamin B 12 Deficiency Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003629 Vitamin B6 Natural products 0.000 description 1
- 229940011671 Vitamin B6 Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000002906 microbiologic Effects 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI19991836 | 1999-08-31 | ||
| FI991836A FI107808B (fi) | 1999-08-31 | 1999-08-31 | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi |
| PCT/FI2000/000733 WO2001016356A1 (en) | 1999-08-31 | 2000-08-30 | Method for identifying an individual at risk for vascular and cancer disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508059A JP2003508059A (ja) | 2003-03-04 |
| JP2003508059A5 true JP2003508059A5 (zh) | 2007-10-11 |
Family
ID=8555217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001520901A Pending JP2003508059A (ja) | 1999-08-31 | 2000-08-30 | 管疾患及び癌の危険性のある人を同定する方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1210452A1 (zh) |
| JP (1) | JP2003508059A (zh) |
| CN (1) | CN1158389C (zh) |
| AU (1) | AU6845600A (zh) |
| FI (1) | FI107808B (zh) |
| RU (1) | RU2247389C2 (zh) |
| WO (1) | WO2001016356A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2453001C1 (ru) * | 2010-10-18 | 2012-06-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипергомоцистеин индуцированного дефицита оксида азота l-норвалином в эксперименте |
| CN114924016B (zh) * | 2022-04-28 | 2024-03-08 | 中国医学科学院北京协和医院 | 同时检测硫酸化及未硫酸化胃泌素g17的方法及其检测试剂盒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI97304C (fi) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | Menetelmä mahasyövän riskin seulonnaksi |
-
1999
- 1999-08-31 FI FI991836A patent/FI107808B/fi active
-
2000
- 2000-08-30 JP JP2001520901A patent/JP2003508059A/ja active Pending
- 2000-08-30 AU AU68456/00A patent/AU6845600A/en not_active Abandoned
- 2000-08-30 EP EP00956556A patent/EP1210452A1/en not_active Ceased
- 2000-08-30 RU RU2002107982/15A patent/RU2247389C2/ru active
- 2000-08-30 WO PCT/FI2000/000733 patent/WO2001016356A1/en active Application Filing
- 2000-08-30 CN CNB008122261A patent/CN1158389C/zh not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heresztyn et al. | Determination of l-arginine and NG, NG-and NG, NG′-dimethyl-l-arginine in plasma by liquid chromatography as AccQ-Fluor™ fluorescent derivatives | |
| Nexø et al. | How to diagnose cobalamin deficiency | |
| JP2577878B2 (ja) | スルフヒドリルアミノ酸類の定量方法 | |
| Still et al. | ACP Broadsheet No 152: March 1998. Clinical implications of plasma homocysteine measurement in cardiovascular disease. | |
| JP2014520265A (ja) | 血漿分離デバイス（ｐｓｄ）から得られる血漿中の総ホモシステイン及びメチルマロン酸のｌｃ−ｍｓ／ｍｓによる分析 | |
| US20110281369A1 (en) | Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry | |
| Amores-Sánchez et al. | Methods for the determination of plasma total homocysteine: a review | |
| Korandji et al. | Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction | |
| JP7385944B2 (ja) | 尿中Ａβアミロイドを検出するためのテストストリップ及び方法 | |
| Hogeling et al. | Quantification of proteins in whole blood, plasma and DBS, with element-labelled antibody detection by ICP-MS | |
| Vernerová et al. | Liquid chromatography method with tandem mass spectrometry and fluorescence detection for determination of inflammatory biomarkers in gingival crevicular fluid as a tool for diagnosis of periodontal disease | |
| Božič-Mijovski | Hyperhomocysteinemia and thrombophilia | |
| US20180259514A1 (en) | Method to detect blood creatinine and an immunosuppressive drug | |
| CN102967713A (zh) | 同型半胱氨酸检测试剂盒及其制备方法 | |
| JP2003508059A5 (zh) | ||
| CN107002017A (zh) | 疏水性半抗原分析物的精确测定测量 | |
| RU2247389C2 (ru) | Способ идентификации индивидуума с риском сосудистого и ракового заболевания | |
| JP3549833B2 (ja) | アフラトキシンとアルブミンの結合物の検出用放射免疫試薬セット及びその検出方法 | |
| Mendis et al. | Association between hyperhomocysteinemia and ischemic heart disease in Sri Lankans | |
| CN103344768B (zh) | 缺血性心脏病检测试剂盒及其应用 | |
| Zvarik et al. | Differences in pteridine urinary levels in patients with malignant and benign ovarian tumors in comparison with healthy individuals | |
| Yokoro et al. | Development of an enzyme-linked immunosorbent assay system for the determination of asymmetric dimethylarginine using a specific monoclonal antibody | |
| US20090311719A1 (en) | In vitro method for diagnosing neurodegenerative diseases | |
| JP2005537022A (ja) | スクリーニングに適応できるホモシステインアッセイ | |
| EP1360499B1 (de) | Bestimmung des zytosolischen nadp-abhängigen malatdecarboxylase-isoenzyms |